- Home
- LPBB vs OSUR Comparison
LPBB vs OSUR Comparison
Compare LPBB & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPBB
- OSUR
- Stock Information
- Founded
- LPBB 2024
- OSUR 2000
- Country
- LPBB United States
- OSUR United States
- Employees
- LPBB N/A
- OSUR N/A
- Industry
- LPBB
- OSUR Medical/Dental Instruments
- Sector
- LPBB
- OSUR Health Care
- Exchange
- LPBB NYSE
- OSUR Nasdaq
- Market Cap
- LPBB 289.8M
- OSUR 266.7M
- IPO Year
- LPBB 2024
- OSUR 1986
- Fundamental
- Price
- LPBB $10.09
- OSUR $3.44
- Analyst Decision
- LPBB
- OSUR Hold
- Analyst Count
- LPBB 0
- OSUR 2
- Target Price
- LPBB N/A
- OSUR $5.50
- AVG Volume (30 Days)
- LPBB 8.5K
- OSUR 1.0M
- Earning Date
- LPBB 01-01-0001
- OSUR 05-07-2025
- Dividend Yield
- LPBB N/A
- OSUR N/A
- EPS Growth
- LPBB N/A
- OSUR N/A
- EPS
- LPBB N/A
- OSUR N/A
- Revenue
- LPBB N/A
- OSUR $185,827,000.00
- Revenue This Year
- LPBB N/A
- OSUR N/A
- Revenue Next Year
- LPBB N/A
- OSUR $8.41
- P/E Ratio
- LPBB N/A
- OSUR N/A
- Revenue Growth
- LPBB N/A
- OSUR N/A
- 52 Week Low
- LPBB $9.97
- OSUR $2.69
- 52 Week High
- LPBB $10.73
- OSUR $6.69
- Technical
- Relative Strength Index (RSI)
- LPBB N/A
- OSUR 45.82
- Support Level
- LPBB N/A
- OSUR $3.40
- Resistance Level
- LPBB N/A
- OSUR $3.55
- Average True Range (ATR)
- LPBB 0.00
- OSUR 0.15
- MACD
- LPBB 0.00
- OSUR 0.02
- Stochastic Oscillator
- LPBB 0.00
- OSUR 56.52
About LPBB LAUNCH TWO ACQUISITION CORP
Launch Two Acquisition Corp is a blank check company.
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.